NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Chlamydia Trachomatis Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact)

出版商 GlobalData 商品編碼 979514
出版日期 內容資訊 英文
沙眼披衣菌檢驗(體外診斷)-全球市場分析及預測模式(COVID-19對市場造成的影響) Chlamydia Trachomatis Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact)
出版日期: 2020年12月15日內容資訊: 英文


一般而言,由於患有由沙眼衣原體感染引起的不育症的男性和女性人數增加,因此在全球範圍內進行的人工授精(AI)或宮內授精(IUI)數正在增加。沙眼衣原體測試模型涵蓋NAAT,多參數CT/NG NAAT和其他CT測試。


  • 主要的產業趨勢洞察
  • 2015年∼2030年各分類市場預測
  • 手術數量,台數,平均銷售價格,各分類市場價值相關詳細資料


  • 各國分析
  • SWOT分析
  • 競爭趨勢


  • 醫療保健制度的各國概要
  • 各國給付方針
  • 國家固有的醫療技術相關法規趨勢

網羅的企業:Hologic Inc,Quidel Corp,Zeptrometrix Corporation,Trinity Biotech Plc,Bio-Rad Laboratories,Becton Dickinson,其他



Product Code: GDME621MM

Chlamydia Trachomatis Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Chlamydia Trachomatis Test market for the year 2020 and beyond. Chlamydia Trachomatis can be transmitted during anal, oral, or vaginal sex. It can also be passed from a mother to her new born child during childbirth. The disease is more common in women and young adults (15-24 years).

In general, the number of Artificial Insemination (AI), or Intrauterine Insemination (IUI), procedures performed globally is growing due to increases in the number of men and women suffering from infertility caused by Chlamydia Trachomatis infection. Chlamydia Trachomatis Test model covers NAATs, Multiparameter CT/NG NAATs and other CT tests.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Chlamydia Trachomatis Test and evolving competitive landscape -

  • Insightful review of the key industry trends.
  • Annualized total Chlamydia Trachomatis Tests market revenue by segment and market outlooks from 2015-2030.
  • Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Chlamydia Trachomatis Tests market.
  • Competitive dynamics insights and trends provided for Chlamydia Trachomatis Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Hologic Inc, Quidel Corp, Zeptrometrix Corporation, Trinity Biotech Plc, Bio-Rad Laboratories, Becton Dickinson and Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.


This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

  • CMO executives who must have deep understanding of the Chlamydia Trachomatis Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

  • Understand the impact of COVID-19 on Chlamydia Trachomatis Tests market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Chlamydia Trachomatis Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Chlamydia Trachomatis Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Chlamydia Trachomatis Tests market from 2015-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.